Portfolio company Cidara Therapeutics acquired by Merck for $9.2B for long-acting antiviral flu therapy.
Cidara Therapeutics is a research-intensive biopharmaceutical company focused on developing important medicines and vaccines, particularly in areas such as oncology, infectious diseases, and immunology
Cidara Therapeutics is a research-intensive biopharmaceutical company focused on developing important medicines and vaccines, particularly in areas such as oncology, infectious diseases, and immunology.